Domov › Akutna limfoblastna levkemija › Illinois
Klinične študije za Akutna limfoblastna levkemija v Illinois
20 študij za Akutna limfoblastna levkemija išče udeležence na lokacijah v Illinois.
Mesta v Illinois
Uradno besedilo študije (angleško)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- OSF Saint Anthony's Health Center, Alton
- Rush-Copley Medical Center, Aurora
- Advocate Outpatient Center - Aurora, Aurora
- in še 54
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
Starost 40–75 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT05334069A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- The University of Chicago Medical Center, Chicago
Vključevanje udeležencevFaza 1/2
30 Days · Vsi spoli · Posodobljeno 16. sep. 2026 · NCT04065399The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- in še 6
Vključevanje udeležencevFaza 1/2
Do 22 let · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT04726241Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Vključevanje udeležencevFaza 2
Starost 7–25 · Vsi spoli · Posodobljeno 19. avg. 2026 · NCT05082519A Study of CTD402 in T-ALL/LBL Patients
- University of Chicago, Chicago
Vključevanje udeležencevFaza 1/2
Starost 1 in več · Vsi spoli · Posodobljeno 19. avg. 2026 · NCT07070219Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
- The University of Chicago, Chicago
Vključevanje udeležencevOpazovalna študija
1 Day – 17 Years · Vsi spoli · Posodobljeno 14. avg. 2026 · NCT06274788Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
- Research Site, Decatur
Vključevanje udeležencevFaza 1/2
Starost 16 in več · Vsi spoli · Posodobljeno 20. jul. 2026 · NCT07155226Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
- Research Site, Chicago
Vključevanje udeležencevFaza 1/2
Starost 12 in več · Vsi spoli · Posodobljeno 13. jul. 2026 · NCT07109219Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
Vključevanje udeležencev
Starost 15 in več · Vsi spoli · Posodobljeno 10. jul. 2026 · NCT06446661A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Northwestern Memorial Hospital, Chicago
- Rush University Medical Center, Chicago
- University of Illinois at Chicago, Chicago
- in še 3
Vključevanje udeležencevOpazovalna študija
Vse starosti · Vsi spoli · Posodobljeno 6. jul. 2026 · NCT01351545Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago
Vključevanje udeležencev
Starost 14 in več · Vsi spoli · Posodobljeno 30. jun. 2026 · NCT03932903Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
- University of Chicago Medical Center, Chicago
Vključevanje udeležencevFaza 1
Starost 18–39 · Vsi spoli · Posodobljeno 29. jun. 2026 · NCT03571321Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
- University of Chicago Medical Center, Chicago
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 5. jun. 2026 · NCT04747912Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Lurie Children's Hospital-Chicago, Chicago
- Advocate Children's Hospital-Oak Lawn, Oak Lawn
- Saint Jude Midwest Affiliate, Peoria
Vključevanje udeležencevOpazovalna študija
Vse starosti · Vsi spoli · Posodobljeno 18. maj 2026 · NCT01790152Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of Chicago, Chicago
Vključevanje udeležencevFaza 1
Starost 13 in več · Vsi spoli · Posodobljeno 5. maj 2026 · NCT04771572A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Northwestern, Chicago
Vključevanje udeležencevFaza 1/2
Starost 12 in več · Vsi spoli · Posodobljeno 24. mar. 2026 · NCT04988555A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 18. mar. 2026 · NCT06207123Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- University of Chicago Comprehensive Cancer Center, Chicago
Vključevanje udeležencevFaza 2
Starost 18–54 · Vsi spoli · Posodobljeno 17. mar. 2026 · NCT06918431Venetoclax Basket Trial for High Risk Hematologic Malignancies
- Ann & Robert H Lurie Children's Hospital of Chicago, Chicago
Vključevanje udeležencevFaza 1
Starost 1–40 · Vsi spoli · Posodobljeno 12. mar. 2026 · NCT05292664Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Vključevanje udeležencevFaza 1
Starost 1–21 · Vsi spoli · Posodobljeno 6. dec. 2024 · NCT05476770Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.